6 Analysts Have This to Say About EastGroup Props

EastGroup Props (NYSE:EGP) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…

EastGroup Props (NYSE:EGP) has observed the following analyst ratings within the last quarter:

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 1 3 2 0 0
Last 30D 1 0 0 0 0
1M Ago 0 0 2 0 0
2M Ago 0 2 0 0 0
3M Ago 0 1 0 0 0

In the last 3 months, 6 analysts have offered 12-month price targets for EastGroup Props. The company has an average price target of $175.5 with a high of $185.00 and a low of $158.00.

Below is a summary of how these 6 analysts rated EastGroup Props over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock

price target chart

This average price target has increased by 4.78% over the past month.

Stay up to date on EastGroup Props analyst ratings.

How Are Analyst Ratings Determined?

Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.

Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Vaccine Player Vaxcyte Has Advantage Over Pfizer, Merck’s Pneumococcal Shots – Analyst Says

The global PCV market, valued at ~$8 billion annually, is poised for significant growth, estimated to reach ~$12 billion soon. Market dynamics are shifting towards adults, potentially doubling with the US discussing vaccination age reduction. Prevnar20 dominates with 97% market share in adults, but Vaxcyte's advanced conjugate capabilities present a competitive advantage.

MRK